Core Viewpoint - Tongce Medical (600763) is actively exploring various ways to reward investors based on actual circumstances and the characteristics of medical services [1] Summary by Categories - Company Actions - The company is considering different methods to give back to investors in response to their support [1]

通策医疗股份有限公司 2025 年第一次临时股东会资料 通策医疗股份有限公司 2025 年第一次临时股东会 会议资料 通策医疗股份有限公司董事会 2025 年 12 月 10 日 1 通策医疗股份有限公司 2025 年第一次临时股东会资料 通策医疗股份有限公司 2025 年第一次临时股东会会议资料目录 一、程序文件 《修订<公司章程>》； 议案 1.02 《修订<股东会议事规则>》； 议案 1.03 《修订<董事会议事规则>》； 议案 1.04 1. 大会会议议程 二、提交股东会审议表决的议案 议案 1 《关于修订<公司章程>及其他制度的议案》； 议案 1.01 《废止<监事会议事规则>》； 议案 1.05 《修订<独立董事工作制度>》； 议案 1.06 《修订<对外投资管理制度>》； 议案 1.07 《修订<关联交易决策制度>》； 议案 1.08 《修订<防范控股股东及关联方占用公司资金制度>》； 议案 1.09 《修订<会计师事务所选聘制度>》； 议案 1.10 《修订<董事、高级管理人员薪酬管理制度>》； 议案 2 《关于取消监事会并免去监事的议案》； 2 通策医疗股份有限公司 2025 年第一次临时股 ...

证券之星消息，截至2025年11月28日收盘，通策医疗(600763)报收于42.05元，上涨0.69%，换手率 0.83%，成交量3.72万手，成交额1.56亿元。 11月28日的资金流向数据方面，主力资金净流出903.7万元，占总成交额5.79%，游资资金净流入425.74 万元，占总成交额2.73%，散户资金净流入477.96万元，占总成交额3.06%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-28 | 42.05 | 0.69% | -903.70万 | -5.79% | 425.74万 | 2.73% | 477.96万 | 3.06% | | 2025-11-27 | 41.76 | -0.33% | -1731.26万 | -10.08% | 838.90万 | 4.88% | 892.36万 | 5.19% | | 2025-11-26 | 41.90 | ...

Core Viewpoint - Tongce Medical (600763) experienced a slight decline in stock price, closing at 41.76 yuan on November 27, 2025, with a trading volume of 41,100 lots and a total transaction amount of 172 million yuan [1]. Group 1: Stock Performance and Trading Data - On November 27, 2025, the stock price decreased by 0.33%, with a net outflow of main funds amounting to 17.31 million yuan, representing 10.08% of the total transaction amount [1][2]. - Retail investors saw a net inflow of 8.92 million yuan, accounting for 5.19% of the total transaction amount, while speculative funds had a net inflow of 0.84 million yuan, making up 4.88% of the total [1][2]. Group 2: Financial Performance and Industry Comparison - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [3]. - The company's third-quarter revenue was 842 million yuan, reflecting a 2.34% year-on-year increase, with a net profit of 192 million yuan, also up 2.31% year-on-year [3]. - Key financial metrics show that Tongce Medical has a total market value of 18.679 billion yuan, a net asset of 4.703 billion yuan, and a net profit margin of 26.91%, ranking 3rd in the industry [3]. Group 3: Analyst Ratings and Target Price - Over the past 90 days, 10 institutions have rated the stock, with 7 buy ratings and 3 hold ratings, and the average target price set by analysts is 51.78 yuan [4].

Core Viewpoint - Tongce Medical (600763) reported a slight decline in stock price, with a closing price of 41.9 yuan on November 26, 2025, down 0.12% from the previous day [1] Financial Performance - For the first three quarters of 2025, Tongce Medical achieved a main business revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year [3] - The third quarter alone saw a main business revenue of 842 million yuan, reflecting a 2.34% increase year-on-year [3] - The company reported a gross profit margin of 41.69% and a net profit margin of 26.91% [3] Market Position - Tongce Medical's total market capitalization is 18.741 billion yuan, ranking 8th in the medical services industry [3] - The company has a price-to-earnings ratio (P/E) of 27.37, significantly lower than the industry average of 366.11, ranking 3rd in the industry [3] - The return on equity (ROE) stands at 11.8%, placing it 5th in the industry [3] Fund Flow Analysis - On November 26, 2025, the net inflow of main funds was 9.8015 million yuan, accounting for 5.38% of the total transaction amount [1][2] - Retail investors experienced a net outflow of 11.9863 million yuan, representing 6.58% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with notable net outflows from retail investors on several days [2] Analyst Ratings - In the last 90 days, 10 institutions have rated the stock, with 7 buy ratings and 3 hold ratings [4] - The average target price set by analysts over the past 90 days is 51.78 yuan [4]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

证券代码：600763 证券简称：通策医疗 公告编号：2025-032 通策医疗股份有限公司 关于召开2025年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东会类型和届次 2025年第一次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 12 月 10 日 15 点 00 分 召开地点：杭州市西湖区西溪路双口井巷 1 号通策医疗大厦 7 楼报告厅 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 12 月 10 日 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 非累积投票议案 | | | | 1.00 | 关于修订《公司章程》及其他制度的议案 | √ | | 1.01 ...

证券之星消息，截至2025年11月20日收盘，通策医疗(600763)报收于43.22元，下跌1.28%，换手率 0.89%，成交量3.99万手，成交额1.74亿元。 11月20日的资金流向数据方面，主力资金净流出1974.79万元，占总成交额11.38%，游资资金净流出 48.71万元，占总成交额0.28%，散户资金净流入2023.5万元，占总成交额11.66%。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净占比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-20 | 43.22 | -1.28% | -1974.79万 | -11.38% | -48. ...

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown stable financial performance with a slight increase in stock price and mixed capital flow data as of November 18, 2025 [1][2][3] Group 2 - As of November 18, 2025, Tongce Medical's stock closed at 44.14 yuan, with a slight increase of 0.05% and a trading volume of 58,200 hands, resulting in a transaction amount of 259 million yuan [1] - The net inflow of main funds was 7.49 million yuan, accounting for 2.9% of the total transaction amount, while retail investors experienced a net outflow of 6.22 million yuan, representing 2.41% of the total transaction amount [1] - In the last five days, the stock has seen fluctuations in capital flow, with significant net outflows from retail investors on several days [1] Group 3 - Key financial metrics for Tongce Medical include a total market value of 19.743 billion yuan, net assets of 4.703 billion yuan, and a net profit of 514 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 2.56% in revenue and 3.16% in net profit [2] - The company's gross profit margin stands at 41.69%, with a net profit margin of 26.91%, indicating strong profitability compared to industry averages [2] - The company ranks well within the industry, with a price-to-earnings ratio of 28.84, placing it third among its peers [2] Group 4 - Over the past 90 days, 11 institutions have rated the stock, with 8 buy ratings and 3 hold ratings, indicating positive sentiment among analysts [3] - The average target price set by institutions for the stock is 51.78 yuan, suggesting potential upside from the current trading price [3]

Core Points - Tongce Medical (600763) closed at 44.68 yuan on November 14, 2025, up 5.4% from 42.39 yuan the previous week [1] - The company's market capitalization is currently 19.985 billion yuan, ranking 9th out of 50 in the medical services sector and 974th out of 5165 in the A-share market [1] Company Announcements - The controlling shareholder, Baoqun Industrial, holds 33.89% of the company's shares and has pledged 21.33 million shares, which accounts for 14.07% of its holdings and 4.77% of the total share capital [2][3] - Baoqun Industrial has also released a pledge of 19.32 million shares, representing 12.74% of its holdings and 4.32% of the total share capital [2][3] - After these changes, Baoqun Industrial has a total of 101.036672 million pledged shares, which is 66.65% of its holdings and 22.59% of the total share capital [2][3] - The associated party, Lv Jianming, holds 0.47% of the shares with no pledges, indicating that the pledge risk is controllable [2][3]